Bristol-Myers Squibb Company (BMY) and Samsung BioLogics Announce Biopharmaceutical Manufacturing Relationship
7/29/2013 10:02:50 AM
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
PRINCETON, N.J. & SEOUL, South Korea--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE:BMY) and Samsung BioLogics today announced the companies have entered into a 10-year agreement under which Samsung BioLogics will manufacture a commercial antibody cancer drug for Bristol-Myers Squibb at its recently completed plant in Songdo Incheon, South Korea. Financial terms were not disclosed. Technology transfer and trial production will commence in July 2013 and commercial production will immediately begin following regulatory approvals.
Help employers find you! Check out all the jobs and post your resume.
comments powered by